Find a pharmacy Healthcare professionals Partnering Press TR EN
Active substance

What is calcium polystyrene sulfonate? Mechanism and research

Calcium polystyrene sulfonate, abbreviated CPS, is an ion-exchange resin that binds potassium in the bowel. It is an active substance studied and used in the medical management of elevated blood potassium.

Published by Aymed İlaç · 17 October 2026

How does it work in the bowel?

The resin exchanges calcium ions for potassium and contributes to potassium removal in stool. Its site of action is the bowel; absorption into the bloodstream is not required. This describes a route of potassium removal that differs from excretion through the kidneys. [1]

Is it a calcium supplement?

The presence of calcium in its name does not make it a nutritional calcium supplement. Its ion-exchange structure and potassium-binding purpose are different. Calcium polystyrene sulfonate and sodium polystyrene sulfonate are also different forms and should be distinguished when reading research. [1, 2]

What outcomes do studies assess?

Clinical studies have examined changes in blood potassium, attainment of target values and adverse effects. A randomised crossover study in hemodialysis patients published in 2018 reported lower potassium levels. Improvement in a laboratory measurement is a different outcome from long-term hospitalisation or survival. [3]

Mechanism and treatment selection

A substance’s ability to bind potassium does not establish that the same approach is suitable for every person or emergency. Potassium level, rate of change, bowel health and other treatments all matter. Severe hyperkalemia requires urgent clinical assessment rather than waiting for an effect at home. [2]

Current guidance and monitoring

Current clinical guidelines are considered alongside individual studies. The UK Kidney Association’s July 2026 update no longer recommends CPS for chronic hyperkalemia and also limits its role in acute care. This assessment should be read alongside studies reporting potassium reduction. Treatment selection and monitoring depend on an individual clinical evaluation. [2]

The articles linked below explain study design and the separate issues of electrolyte monitoring, bowel safety and interactions with oral medicines.

All articles on this topic

References

  1. Calcium Resonium UK SmPC
  2. UKKA: Management of hyperkalaemia in adults, updated July 2026
  3. Wang ve ark. Calcium-polystyrene sulfonate in maintenance hemodialysis: randomized crossover study, 2018

This article provides general health information. Consult your clinician for individual diagnosis and treatment decisions, and your pharmacist for questions about medicine use.

Published by Aymed İlaç · 17 October 2026